Skip to main content
Clinical Trials/ISRCTN96883876
ISRCTN96883876
Completed
未知

Growth hormone treatment of children after IntraUterine Growth Retardation: IUGR-2 study

Erasmus Medical Centre (The Netherlands)0 sites170 target enrollmentJanuary 27, 2006

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Erasmus Medical Centre (The Netherlands)
Enrollment
170
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 27, 2006
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Erasmus Medical Centre (The Netherlands)

Eligibility Criteria

Inclusion Criteria

  • 1\. Birth weight less than P3 for gestational age (according to Usher and McLean)
  • 2\. Neonatal period without signs of severe asphyxia (defined by Apgar score less than 3 after 5 minutes), without signs of chronic lung disease (such as bronchopulmonary dysplasia)
  • 3\. No catch\-up growth defined as obtaining a height of P3 within the first 2 years of life or at a later stage
  • 4\. Height velocity (cm/year) for chronological age P50
  • 5\. Chronological age at the start of treatment: 3\.0 \- 7\.99 years (boys and girls)
  • 6\. Prepubertal signs defined as Tanner stage 1 or testicular volume less than 4 ml
  • 7\. Well documented growth data from birth up to 2 years and at least 1 year before the start of the study

Exclusion Criteria

  • 1\. Any endocrine or metabolic disorder such as diabetes mellitus, diabetes insipidus, hypothyroidism or inborn errors of metabolism, except of GHD
  • 2\. Disorders of genito\-urinary tract, cardiopulmonary or gastrointestinal tract, or nervous systems, nutritional and/or vitamin deficiencies
  • 3\. Chromosomal abnormalities or signs of a syndrome, except of Silver\-Russell Syndrome (SRS)
  • 4\. Chondrodysplasia
  • 5\. Hydrocephalus
  • 6\. Active malignancy or increased risk of leukaemia
  • 7\. Serious suspicion of psychosocial dwarfism (emotional deprivation)
  • 8\. Previous anabolic sex steroid or GH therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Treatment with recombinant Growth Hormone in Children born Small for Gestational Age (SGA) without Catch-up Growth. - Not applicableShort stature in children born small for gestational age without catch up growth
EUCTR2005-001507-19-IEational Children's Hospital & Trinity College Dublin350
Completed
Not Applicable
Growth Hormone Treatment of Children after Intrauterine Growth Retardation (IUGR-1 study).1. Small for gestational age (SGA)<br /> 2. Intrauterine growth retardation (IUGR).
NL-OMON26748ovo Nordisk A/S, Denmark90
Completed
Not Applicable
Effects of growth hormone treatment after final height in Prader-Willi SyndromePrader Willi SyndromeNutritional, Metabolic, EndocrineDisorders of other endocrine glands
ISRCTN24648386Dutch Growth Foundation (Netherlands)20
Active, not recruiting
Phase 1
Effects of growth hormone treatment after final height in Prader-Willi Syndrome: A double-blind multicenter, cross-over study on the effects of growth hormone versus placebo on body composition and psychosocial behaviour in transition - Effects of GH after final height in PWSPrader-Willi SyndromeMedDRA version: 9.1Level: LLTClassification code 10036476Term: Prader-Willi syndrome
EUCTR2007-004716-31-NLDutch Growth Foundation
Completed
Not Applicable
Effects of growth hormone treatment after final height in Prader-Willi Syndrome: A double-blind multicenter, cross-over study on the effects of growth hormone versus placebo on body composition and psychosocial behaviour in transitioPrader-Willi Syndrome10029299
NL-OMON39086Erasmus MC, Universitair Medisch Centrum Rotterdam26